Theravance Biopharma, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2012 | $-119.1M | $-121.7M | $2.6M | $21.3M |
| FY2013 | $-121.0M | $-123.7M | $2.7M | $22.5M |
| FY2014 | $-175.2M | $-178.3M | $3.1M | $43.2M |
| FY2015 | $-168.9M | $-171.5M | $2.6M | $54.1M |
| FY2016 | $-99.0M | $-101.1M | $2.1M | $41.2M |
| FY2017 | $-201.1M | $-203.5M | $2.4M | $49.1M |
| FY2018 | $-112.9M | $-120.1M | $7.2M | $51.3M |
| FY2019 | $-238.2M | $-241.4M | $3.2M | $60.5M |
| FY2020 | $-250.4M | $-257.0M | $6.6M | $63.0M |
| FY2021 | $-207.9M | $-211.3M | $3.4M | $62.1M |
| FY2022 | $-187.0M | $-187.6M | $572.0K | $39.7M |
| FY2023 | $-27.0M | $-29.5M | $2.5M | $25.4M |
| FY2024 | $-11.5M | $-11.9M | $332.0K | $21.4M |
| FY2025 | $238.5M | $238.5M | $42.0K | $18.5M |